Having trouble accessing articles? Reset your cache.

Product Development
FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV

FDA's approval of Vyepti eptinezumab-jjmr from Lundbeck is the first for an IV-delivered CGRP inhibitor for migraine prevention, but the therapy will face competition from ...

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T ...

Esperion enters crowded LDL-lowering market with FDA approval of Nexletol

Esperion marks its transition to a commercial-stage company with FDA's approval of Nexletol bempedoic acid as an adjunct to maximally tolerated statin therapy for the treatment of ...

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial ...

Translation in Brief
Storm's open-access algorithm for RNA epigenetics; plus Duke studies show checkpoint blockers promote anti-HIV bNAbs and reduce opioid efficacy

Algorithm from Storm and academic collaborators for high-throughput analysis of RNA epigenetics

Storm Therapeutics Ltd. and collaborators at the University of ...

Management Tracks
Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating ...

BioCentury ISSN 1097-7201